Excessive toxicities of pegylated asparaginase in pediatric acute lymphoblastic leukemia patients with high body surface area: A call for action
- PMID: 33009863
- DOI: 10.1002/pbc.28743
Excessive toxicities of pegylated asparaginase in pediatric acute lymphoblastic leukemia patients with high body surface area: A call for action
References
REFERENCES
-
- Miller DR, Leikin S, Albo V, Sather H, Karon M, Hammond D. Intensive therapy and prognostic factors in acute lymphoblastic leukemia of childhood: CCG 141. A report from Childrens Cancer Study Group. Haematol Blood Transfus. 1981;26:77-86.
-
- Ortega JA, Nesbit ME Jr. L-Asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia. Cancer Res. 1977;37(2):535-540.
-
- Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999;13(3):335-342.
-
- Panetta JC, Gajjar A, Hijiya N, et al. Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia. Clin Pharmacol Ther. 2009;86(6):651-658.
-
- Kurtzberg J, Asselin B, Bernstein M, Buchanan GR, Pollock BH, Camitta BM. Polyethylene glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866). J Pediatr Hematol Oncol. 2011;33(8):610-616.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
